Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EPS (Weighted Average and Diluted) (2023 - 2026)

Rallybio's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$1.52 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 84.05% to -$1.52 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.59, a 85.04% increase, with the full-year FY2025 number at -$1.59, up 85.01% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$1.52 in Q4 2025 for Rallybio, down from $0.36 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for RLYB hit a ceiling of $0.36 in Q3 2025 and a floor of -$9.53 in Q4 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.17 across 3 years, with a median of -$0.44 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 1844.9% in 2024 and later skyrocketed 238.46% in 2025.
  • Tracing RLYB's EPS (Weighted Average and Diluted) over 3 years: stood at -$0.49 in 2023, then plummeted by 1844.9% to -$9.53 in 2024, then skyrocketed by 84.05% to -$1.52 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RLYB at -$1.52 in Q4 2025, $0.36 in Q3 2025, and -$0.22 in Q2 2025.